First symptom guides diagnosis and prognosis in neurodegenerative diseases—a retrospective study of autopsy proven cases

Clinical diagnostic criteria for neurodegenerative diseases have been framed based on clinical phenomenology. However, systematic knowledge about the first reported clinical symptoms in neurodegenerative diseases is lacking. Therefore, the aim was to determine the prevalence and clinical implications of the first clinical symptom (FS) as assessed by medical history in neuropathologically proven neurodegenerative diseases.

[1]  V. Mok,et al.  Predictors of survival in frontotemporal lobar degeneration syndromes , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  Sonja W. Scholz,et al.  Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study , 2020, The Lancet Neurology.

[3]  A. Danek,et al.  Seizures in Alzheimer’s disease are highly recurrent and associated with a poor disease course , 2020, Journal of Neurology.

[4]  John L. Robinson,et al.  Distribution patterns of tau pathology in progressive supranuclear palsy , 2020, Acta Neuropathologica.

[5]  J. Klein,et al.  Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome , 2019, JAMA neurology.

[6]  D. Mann,et al.  Symmetric dimethylation of poly-GR correlates with disease duration in C9orf72 FTLD and ALS and reduces poly-GR phase separation and toxicity , 2019, Acta Neuropathologica.

[7]  Nick C Fox,et al.  Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study , 2019, The Lancet Neurology.

[8]  A. Danek,et al.  Identification of a rare presenilin 1 single amino acid deletion mutation (F175del) with unusual amyloid-β processing effects , 2019, Neurobiology of Aging.

[9]  A. Sinclair,et al.  Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype , 2019, Alzheimer's & Dementia.

[10]  J. Morris,et al.  Seizures as an early symptom of autosomal dominant Alzheimer's disease , 2019, Neurobiology of Aging.

[11]  J. Morris,et al.  Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. , 2019, Brain : a journal of neurology.

[12]  A. Lees,et al.  Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[13]  T. Uchihara,et al.  Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB consortium , 2018, Neurology.

[14]  Murray Grossman,et al.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.

[15]  Adrian Danek,et al.  Neurological manifestations of autosomal dominant familial Alzheimer’s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) , 2016, The Lancet Neurology.

[16]  J. Rowe,et al.  Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes , 2016, Neurology.

[17]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[18]  O. Hardiman,et al.  A revision of the El Escorial criteria - 2015 , 2015, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[19]  Murray Grossman,et al.  Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine , 2015, Acta Neuropathologica.

[20]  Donald A. Wilson,et al.  At the interface of sensory and motor dysfunctions and Alzheimer's disease , 2015, Alzheimer's & Dementia.

[21]  E. Tolosa,et al.  The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases , 2014, Movement disorders : official journal of the Movement Disorder Society.

[22]  N. Jetté,et al.  The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[23]  W. Poewe,et al.  Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group , 2014, Movement disorders : official journal of the Movement Disorder Society.

[24]  R. Armstrong.  Factors Determining Disease Duration in Alzheimer's Disease: A Postmortem Study of 103 Cases Using the Kaplan-Meier Estimator and Cox Regression , 2014, BioMed research international.

[25]  J. Weuve,et al.  Alzheimer disease in the United States (2010–2050) estimated using the 2010 census , 2013, Neurology.

[26]  Xiao-Chun Chen,et al.  Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review , 2013, Translational Neurodegeneration.

[27]  Mark Hallett,et al.  Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.

[28]  D. Dickson.  Parkinson's disease and parkinsonism: neuropathology. , 2012, Cold Spring Harbor perspectives in medicine.

[29]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[30]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[31]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[32]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[33]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[34]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[35]  J. Schneider,et al.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration , 2007, Acta Neuropathologica.

[36]  K. Nakashima,et al.  Prevalence of progressive supranuclear palsy in Yonago, Japan , 2004, Movement disorders : official journal of the Movement Disorder Society.

[37]  F. Tison,et al.  Prevalence of multiple system atrophy , 2000, The Lancet.

[38]  Y Ben-Shlomo,et al.  Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study , 1999, The Lancet.

[39]  D. Maraganore,et al.  Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990 , 1997, Neurology.

[40]  I Litvan,et al.  Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[41]  I Litvan,et al.  Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.

[42]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[43]  Hans Kretzschmar,et al.  Brain banking: opportunities, challenges and meaning for the future , 2009, Nature Reviews Neuroscience.

[44]  J. Trojanowski,et al.  Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations , 2008, Acta Neuropathologica.

[45]  John R. Hodges,et al.  Epidemiology of frontotemporal dementia , 2007 .

[46]  C. Tanner,et al.  Epidemiologic aspects. , 2000, Advances in neurology.

[47]  G. Lennox.  Lewy body dementia. , 1992, Bailliere's clinical neurology.